2. The combination of a b-blocker, an ACE inhibitor or ARB, and a thiazide or thiazide-like diuretic should also be considered in the absence of a prior MI, LV systolic dysfunction, diabetes mellitus, or proteinuric CKD .
3. If b-blockers are contraindicated or produce intolerable side effects, a nondihydropyridine CCB (such as diltiazem or verapamil) may be substituted, but not if there is LV dysfunction .
4. If either the angina or the hypertension remains uncontrolled, a long-acting dihydropyridine CCB can be added to the basic regimen of b-blocker, ACE inhibitor, and thiazide or thiazide-like diuretic.
5. There are no special contraindications in hypertensive patients for the use of antiplatelet or anticoagulant drugs, except that in patients with uncontrolled severe hypertension who are taking antiplatelet or anticoagulant drugs, the BP should be lowered without delay to reduce the risk of hemorrhagic stroke .
Patients with ACS and HTN 1. If there is no contraindication to the use of b-blockers, in patients with ACS, the initial therapy of hypertension should include a short-acting b1-selective b-blocker without intrinsic sympathomimetic activity (metoprolol tartrate or bisoprolol). b-Blocker therapy should typically be initiated orally within 24 hours of presentation . For patients with severe hypertension or ongoing ischemia, an intravenous bblocker (esmolol) can be considered .
2. In patients with ACS and hypertension, nitrates should be considered to lower BP or to relieve ongoing ischemia or pulmonary congestion 3. If there is a contraindication to the use of a b-blocker or intolerable side effects, then a nondihydropyridine CCB such as verapamil or diltiazem may be substituted for patients with ongoing ischemia.
4. An ACE inhibitor or an ARB should be added if the patient has an anterior MI, if hypertension persists, if the patient has evidence of LV dysfunction or HF, or if the patient has diabetes mellitus. For lower risk ACS patients with preserved LV ejection fraction and no diabetes mellitus, ACE inhibitors can be considered a first-line agent for BP control .
5. Aldosterone antagonists are indicated for patients who are already receiving b-blockers and ACE inhibitors after MI and have LV dysfunction and either HF or diabetes mellitus.
6. Loop diuretics are preferred over thiazide and thiazidetype diuretics for patients with ACS who have HF (NYHA class III or IV) or for patients with CKD and an estimated glomerular filtration rate <30 mL/min.
For patients with persistent hypertension not controlled with a b-blocker, an ACE inhibitor, and an aldosterone antagonist, a thiazide or thiazide-type diuretic may be added in selected patients for BP control . 7. In patients who have hypertension and HF with preserved ejection fraction, the recommendations are to control systolic and diastolic hypertension ventricular rate in the presence of atrial fibrillation and pulmonary congestion and peripheral edema .
Treatment of Hypertension in Patients with CAD
8. Use of b-adrenergic blocking agents, ACE inhibitors, ARBs, or CCBs in patients with HF with preserved ejection fraction and hypertension may be effective to minimize symptoms of HF .
9. In IHD, the principles of therapy for acute hypertension with pulmonary edema are similar to those for STEMI and NSTEMI, as described above .
